AS
ANIK icon

Altshuler Shaham’s Anika Therapeutics ANIK Stock Holding History

Altshuler Shaham’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,957
Closed -$57.9K – 377
2022
Q4 		$57.9K Buy
+1,957
New +$55.7K ﹤0.01% 197
2019
Q4 		– Sell
-167
Closed -$9K – 499
2019
Q3 		$9K Buy
+167
New +$8.57K ﹤0.01% 288

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Altshuler Shaham's ANIK Position: Q1 2023 in Review

Altshuler Shaham sold out of Anika Therapeutics (ANIK) in Q1 2023, closing a stake of 1,957 shares — an estimated $57.9K sold.

Altshuler Shaham first reported a position in ANIK in Q3 2019 and held it in 2 quarters. The position peaked at $57.9K in Q4 2022. 119 funds tracked by Wall St. Rank hold ANIK as of Q1 2023.

  • Altshuler Shaham reported no remaining Anika Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Altshuler Shaham sold 1,957 Anika Therapeutics shares in Q1 2023, an estimated $57.9K.
  • Altshuler Shaham first reported a position in Anika Therapeutics in Q3 2019 and held it in 2 quarters.
  • Altshuler Shaham's Anika Therapeutics position peaked at $57.9K in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2023.

Based on Altshuler Shaham's 13F filing for Q1 2023, filed 9 May 2023.